Adaptimmune

@Adaptimmune

Adaptimmune is a multinational, clinical-stage company focused on developing novel immunotherapies that can potentially transform cancer treatment

Vrijeme pridruživanja: srpanj 2015.

Tweetovi

Blokirali ste korisnika/cu @Adaptimmune

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @Adaptimmune

  1. prije 13 sati

    On the issued this report (). Prevention and management are key - especially for rarer indications such as . Our teams work hard to discover and develop new treatments.

    Poništi
  2. 4. velj

    It is - This word cloud summarizes key words from the statements shared by colleagues in our company. We are committed to developing innovative cell therapies aiming to transform the lives of people with .

    Poništi
  3. 3. velj

    A key topic today at & GIST symposium has been the importance of network for rare communities. A Trama praises the referral in allowing exchange between physicians. This is why we are here meeting physicians & patient groups.

    Poništi
  4. proslijedio/la je Tweet
    3. velj

    We are stronger when we work together: patients, clinicians, researchers, scientists, and advocates. An entire session facilitating our common goals

    , , i još njih 7
    Poništi
  5. 31. sij

    cells may cause CAR T-cell resistance ( article: ). This may create even more of a challenge for solid tumors. We saw high PD1 levels in a non-responder with ADP-A2M4 and we are working on a combination trial with a PD1 checkpoint inhibitor.

    Poništi
  6. 30. sij

    "Next week, we will be meeting with some of our SPEARHEAD-1 investigators, as well as patient groups and other partners, during the & GIST symposium. Let us know if you would want to meet. "

    Poništi
  7. 29. sij

    We are committed to delivering new therapies to people with synovial . There is still a high unmet medical need for treatment of this and we are recruiting patients in our Phase 2 SPEARHEAD-1 now ().

    Poništi
  8. 27. sij

    Check out this article () by in talking about the powerful potential of ADP-A2M4 to help with synovial . Our Phase 2 SPEARHEAD-1 is enrolling now - click below to learn more.

    Poništi
  9. 23. sij

    We opened our first EU site in , enrolling patients w/ synovial & MRCLS in the Phase 2 trial SPEARHEAD-1. We will open more sites in Spain, as well as and . Check out this video in Spanish on how SPEAR T-cells work.

    Poništi
  10. 22. sij

    Our updates did not include our Phase 2 SPEARHEAD-1 for patients with synovial and MRCLS. We are progressing well and the trial is open at ~20 sites in US & Spain, with sites in UK and France opening soon. Click below to learn more.

    Poništi
  11. 21. sij

    The responses in 4 solid tumors, in addition to our data in synovial , demonstrate the value of our SPEAR T-cell therapies for people with and validate the importance of our proprietary affinity engineering. Click the picture to read our recent press release.

    Poništi
  12. 16. sij

    Following , our team is reflecting on all the exhilarating announcements that we made over the past few days. If you missed our news, you can find the full press releases here:

    Poništi
  13. 15. sij

    On Monday, we announced that we have seen partial responses in 4 additional solid tumor indications – beyond the responses already observed in synovial . Read the press release here:

    Poništi
  14. 14. sij

    Recap: we shared three exciting announcements regarding responses in multiple , a partnership with , and appointment of our CMO. Learn more here in our news section:

    Poništi
  15. 14. sij

    NEWS: Today, we announced a partnership with to bring new stem-cell derived allogeneic T-cell therapies to patients. Read the details of the deal here:

    Poništi
  16. 13. sij

    We have an exciting leadership update! Dr. Elliot Norry has been appointed as Chief Medical Officer. After being with for the past 4 years, we could not be more grateful that he will continue to be part of our team. Read more here:

    Poništi
  17. 13. sij

    NEWS: We are thrilled to share with the community that we have seen partial responses in 4 additional solid tumor indications – beyond the responses already observed in synovial ! Read the press release here:

    Poništi
  18. 9. sij

    We are recruiting for our SURPASS in , , & at , , and . We are looking for patients with multiple indications - click below to learn more.

    Poništi
  19. 7. sij

    Check out this article in featuring of discussing our ADP-A2M4 in synovial and how it is a "game changer" for with this deadly . Click below to read the full article.

    Poništi
  20. 6. sij

    We hope everyone had a good holiday season. We are back to work to deliver for patients with . Reach out to meet with management or to schedule an interview at :

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·